Search
Simcere Pharmaceutical/Antikang Bio Applies for Marketing of Groundbreaking Pediatric Anti-Influenza Drug
2025-09-04 /
Read about 0 minute
Author：小编
China's pioneering pediatric anti-influenza virus drug, Madunavir (brand name: Xilin Da®), has successfully concluded Phase III clinical trials and is now seeking marketing approval. By effectively inhibiting the Cap-dependent endonuclease essential for influenza virus replication, this medication precisely halts viral mRNA transcription, offering the potential for a 'one-dose cure' for pediatric influenza. Furthermore, Madunavir has been authorized for post-exposure prophylaxis against both influenza A and B in individuals aged two and older.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
